Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The levels of ZnT8A were measured in 2,239 British type 1 diabetic individuals diagnosed before age 17 years, with a median duration of diabetes of 4 years.
|
22526605 |
2012 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In both animal models of diabetes, ZnT8 expression was remarkably downregulated in the early stage of diabetes.
|
21099260 |
2011 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 31 Somali children ≤19 yr were treated for type 1 diabetes (T1D) at the University of Minnesota Masonic Children's Hospital and Children's Hospitals and Clinics of Minnesota underwent analysis of human leukocyte antigen (HLA) alleles (n = 30) and diabetes autoantibodies [glutamic acid decarboxylase (GAD65), islet antigen 2 (IA-2), zinc transporter 8 (ZnT8); n = 31].
|
26854192 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we characterize an emerging role of ZnT-8 in diabetes and discuss potential mechanisms of its involvement in the etiology of both forms of diabetes.
|
19655390 |
2009 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Diabetes Susceptibility Gene SLC30A8 that Encodes the Zinc Transporter ZnT8 is a Pseudogene in Guinea Pigs Potentially Contributing to Low Guinea Pig Islet Zinc Content.
|
30392157 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blood samples were obtained from 900 patients with age from 1 month to 25 years (median age 11.1 years) within 2 weeks of diabetes onset to test anti-islet autoantibodies to insulin (IAA), glutamic acid decarboxylase (GADA), insulinoma antigen (IA-2AA), the zinc transporter-8 (ZnT8AA), and islet-cell antibodies (ICA).
|
21138544 |
2011 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 97 subjects with diabetes onset before age 25, a random C-peptide ≥0.1 ng/mL, and negative for all diabetes autoantibodies (GADA, IA-2, ZnT8, and IAA) were enrolled, after excluding 21 subjects with secondary diabetes or refusal to participate.
|
26059258 |
2016 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The use of GADAs, IA-2As, and ZnT8As in combination allowed a stratification of clinical phenotype, with younger age of onset of diabetes and characteristics of more severe insulin deficiency (higher fasting glucose and A1C, lower BMI, total cholesterol, and triglycerides) in patients with all three markers, with progressive attenuation in patients with two, one, and no antibodies (all P(trend) < 0.001).
|
19808923 |
2010 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Children, younger than 15 years of age (n = 723) who were newly diagnosed with diabetes, were analyzed for ZnT8A, other diabetes-associated autoantibodies, HLA DR-DQ alleles, and metabolic status, which was monitored by pH, plasma glucose, and occurrence of ketoacidosis at diagnosis and through follow-up of C-peptide concentrations, exogenous insulin dose, and glycosylated hemoglobin for 2 years after the diagnosis.
|
26519333 |
2016 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
ZnT8-ab are associated with more acute diabetes onset.
|
29327148 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
ZnT8-ab positive patients had higher titre and more frequent occurrence of multiple diabetes-related autoantibodies than ZnT8-ab negative patients.
|
30465779 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prevalence of diabetes and presence of autoantibodies against zinc transporter 8 and glutamic decarboxylase at diagnosis and at follow up of Graves' disease.
|
30783963 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
It argues against ZnT8 autoimmunity arising from molecular mimicry and suggests a mechanistic link between the two major forms of diabetes.
|
18591387 |
2008 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, Znt8 Arg-325 risk variant shows an enhanced inflammatory response upon LPS stimulation that might aggravate insulin resistance and the progression of diabetes cardiovascular complications.
|
30142362 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Other outcomes are: (1) Any persistent confirmed beta-cell autoantibody (glutamic acid decarboxylase (GADA), IA-2A, autoantibodies to insulin (IAA) and zinc transporter 8 or tetraspanin 7), or diabetes, (2) Persistent confirmed IAA, (3) Persistent confirmed GADA and (4) Abnormal glucose tolerance or diabetes.
|
31256036 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present review, we summarize the literature about clinical aspects of ZnT8 in the pathogenesis of diabetes, and suggest that ZnT8 might play a different role between type 1 diabetes mellitus and type 2 diabetes mellitus.
|
27181765 |
2016 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A registry-based group of 288 persistently autoantibody-positive (Ab(+)) offspring/siblings (aged 0-39 years) of known patients (Ab(+) against insulin, GAD, IA-2 and/or ZnT8) were typed for HLA-DQ, -A and -B and monitored from the first Ab(+) sample for development of diabetes within 5 years.
|
23712485 |
2013 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
ZnT8 was therefore proposed as a therapeutic target for diabetes, and recent genome-wide association studies identified polymorphisms in the ZNT8 gene conferring increased type 2 diabetes risk.
|
19095428 |
2009 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Diabetes Autoimmunity Study in the Young (DAISY) followed prospectively for development of persistent IA (autoantibodies to insulin, GAD65, IA-2, or ZnT8 on at least two consecutive exams) and diabetes 1715 non-Hispanic white children at increased genetic risk for T1D.
|
22776074 |
2012 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, those with later onset type 1 diabetes had a modestly lower type 1 diabetes genetic risk score (0.268 vs 0.279; p < 0.001 [expected type 2 diabetes population median, 0.231]), a higher islet autoantibody prevalence (GAD-, islet antigen 2 [IA2]- or zinc transporter protein 8 [ZnT8]-positive) of 78% at 13 years vs 62% at 26 years of diabetes duration; (p = 0.02), and were less likely to identify as having type 1 diabetes (79% vs 100%; p < 0.001) vs those with young-onset disease.
|
30969375 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The breakthrough discovery that the common polymorphism in zinc transporter <i>SLC30A8</i>/ZnT8 may increase susceptibility to type 2 diabetes provided novel insights into the role of zinc in diabetes.
|
29415457 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
ZnT8-TripleA was detected in 1678 (65%) patients with T1D, 4 (9%) T2D, 3 (11%) MODY and in none (0%) of the patients with secondary diabetes.
|
21708156 |
2011 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Autoantibody-negative patients were retested at median diabetes duration of 3.2 yr (range 0.9-16.2) for autoantibodies (GAD, IA2, ZnT8), human leukocyte antigen (HLA) typing, non-fasting C-peptide, and sequencing of HNF4A, HNF1A, KCNJ11, and INS.
|
21518407 |
2011 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Loss of ZnT8 function protects against diabetes by enhanced insulin secretion.
|
31676859 |
2019 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite the emerging consensus on the role of ZnT8 in glucose homeostasis, a recent genetic study in humans has unexpectedly identified loss-of-function SLC30A8 mutants that are associated with protection from diabetes.
|
25287711 |
2015 |